Neurology

By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.

Pharmacists are crucial in Elevidys administration, ensuring accurate dosing, coordinating treatment timing, and managing adverse effects to optimize patient outcomes.

Long-acting injectables offer a promising approach to schizophrenia treatment, but their effective use requires careful management and patient education.

Currently, EN001 is undergoing evaluation in a phase 1b trial.

Elevidys offers significantly higher dystrophin production than existing Duchenne muscular dystrophy treatments but requires intensive monitoring for adverse events.

Given the increasing age of patients with generalized myasthenia gravis, knowing which therapies are most effective for different subgroups is essential.

LAIs offer a variety of benefits, from improved medication adherence and relapse prevention to enhanced quality of life for individuals with schizophrenia.

Amlenetug could provide a treatment option for patients with multiple system atrophy, a progressive and rare condition that causes damage to the brain’s nerve cells.

Risdiplam is the only approved non-invasive disease-modifying SMA treatment.

Supplements, such as Prevagen, as well as lifestyle and diet modifications can provide additional support to patients with Alzheimer disease.

Compared with other treatments for myasthenia gravis, nipocalimab demonstrated more significant improvements in disability scores, with tolerable safety.

Pregnant individuals with multiple sclerosis (MS) are more likely to experience mental illness both during their pregnancy and in the first years after giving birth.

The approval marks the first subcutaneous infusion device approved for the treatment of Parkinson disease, providing a new option for patients with serious disease who are unresponsive to other therapies.

Health care professionals, particularly pharmacists, can recommend that patients take over-the-counter supplements, such as melatonin, to facilitate REM sleep.

Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.

Administered every 4 weeks, the approval could serve as a breakthrough for easier and more effective care for patients with early Alzheimer disease.

Pharmacists bridge communication gaps and enhance shared decision-making.

Memantine/donepezil and everolimus are used to treat dementia of the Alzheimer type and tuberous sclerosis complex-associated subependymal giant cell astrocytoma, respectively.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

These drugs are set to revolutionize their respective disease states in 2025.

The finding could help better treat patients with long COVID, as pharmacists and treatment providers can look out for ME/CFS symptoms.

Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.

Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.

Hokkaido scallop oil plasmalogen and Apoaequorin have both been posited to improve brain health.

If approved, nipocalimab can treat antibody positive individuals with generalized myasthenia gravis.

The pharmacist’s role includes educating and making recommendations, collaborating with health care professionals, and observing early signs of cognitive impairment in patients during interactions.

Duchenne muscular dystrophy is an incurable neuromuscular disorder that can lead to cardiomyopathy, resulting in heart failure.

These inequalities, which can include socioeconomic disparities, show neurological changes associated with aging and dementia.

Researchers recommend early vaccination against herpes zoster to mitigate the risks.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.